BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

901 related articles for article (PubMed ID: 26690614)

  • 1. Chronic lymphocytic leukemia (CLL)-Then and now.
    Rai KR; Jain P
    Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
    Takizawa J
    Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
    Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
    Vitale C; Burger JA
    Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New insights in the treatment of chronic lymphocytic leukemia and role of the biologist in the monitoring of the treatments].
    Troussard X; Cornet É
    Ann Biol Clin (Paris); 2016; 74(2):176-83. PubMed ID: 27029723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy-free treatment of chronic lymphocytic leukemia?].
    Wendtner CM
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2104-6. PubMed ID: 24085367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.